Answer
Very common non-gastrointestinal adverse reactions with zolbetuximab (Vyloy) combined with fluoropyrimidine- and platinum-containing chemotherapy are hypoalbuminemia, decreased appetite, peripheral oedema and decreased weight.
Sources for this answer
- Vyloy powder for concentrate for solution for infusionAstellas Pharma Ltd · emc · SmPC §4.8 Undesirable effects · Version 6Document updated
Sources checked